These co-senior authors contributed equally to this work.
Differentiation and regeneration potential of mesenchymal progenitor cells derived from traumatized muscle tissue
Article first published online: 24 OCT 2011
© 2011 The Authors Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Journal of Cellular and Molecular Medicine
Volume 15, Issue 11, pages 2377–2388, November 2011
How to Cite
Jackson, W. M., Lozito, T. P., Djouad, F., Kuhn, N. Z., Nesti, L. J. and Tuan, R. S. (2011), Differentiation and regeneration potential of mesenchymal progenitor cells derived from traumatized muscle tissue. Journal of Cellular and Molecular Medicine, 15: 2377–2388. doi: 10.1111/j.1582-4934.2010.01225.x
Views expressed in this manuscript are those of the authors alone, and do not reflect those of the United States Government, the United States Army or the Department of Defence. Nor do they reflect those of the National Institutes of Health or the Department of Health and Human Services.
- Issue published online: 24 OCT 2011
- Article first published online: 24 OCT 2011
- Accepted manuscript online: 3 DEC 2010 10:37AM EST
- Received: May 8, 2010; Accepted: November 29, 2010
- mesenchymal stem cells;
- progenitor cells;
- tissue engineering;
- regenerative medicine;
Mesenchymal stem cell (MSC) therapy is a promising approach to promote tissue regeneration by either differentiating the MSCs into the desired cell type or by using their trophic functions to promote endogenous tissue repair. These strategies of regenerative medicine are limited by the availability of MSCs at the point of clinical care. Our laboratory has recently identified multipotent mesenchymal progenitor cells (MPCs) in traumatically injured muscle tissue, and the objective of this study was to compare these cells to a typical population of bone marrow derived MSCs. Our hypothesis was that the MPCs exhibit multilineage differentiation and expression of trophic properties that make functionally them equivalent to bone marrow derived MSCs for tissue regeneration therapies. Quantitative evaluation of their proliferation, metabolic activity, expression of characteristic cell-surface markers and baseline gene expression profile demonstrate substantial similarity between the two cell types. The MPCs were capable of differentiation into osteoblasts, adipocytes and chondrocytes, but they appeared to demonstrate limited lineage commitment compared to the bone marrow derived MSCs. The MPCs also exhibited trophic (i.e. immunoregulatory and pro-angiogenic) properties that were comparable to those of MSCs. These results suggest that the traumatized muscle derived MPCs may not be a direct substitute for bone marrow derived MSCs. However, because of their availability and abundance, particularly following orthopaedic injuries when traumatized muscle is available to harvest autologous cells, MPCs are a promising cell source for regenerative medicine therapies designed to take advantage of their trophic properties.